



REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME

tixagevimab/cilgavimab

Effective Date: September 2022
Revised Date:
Reviewed Date:

CLASSIFICATION
Antiviral

OTHER NAMES
Evusheld

PAGE
 1 of 1

ADMINISTRATION POLICY:

IM: - May be administered by a nurse
IV bolus/intermittent/Subcut: - *Do not give*

RECONSTITUTION/DILUTION/ADMINISTRATION:

Available as: 100 mg/mL vial. Store in refrigerator. Do not shake.

IM: Administer each component as separate injections at two separate injection sites (preferably one into each of the gluteal muscles)

Maximum concentration: 100 mg/mL

DOSAGE:

Usual: tixagevimab 300 mg (3 mL) and cilgavimab 300 mg (3 mL) IM once

Maximum single dose: tixagevimab 300 mg (3 mL) and cilgavimab 300 mg (3 mL)

Maximum daily dose: tixagevimab 300 mg (3 mL) and cilgavimab 300 mg (3 mL)

STABILITY/COMPATIBILITY:

Stability of Final Admixture: 4 hours at room temperature or refrigerated once withdrawn into a syringe

Compatibility: Do not mix with other drugs

PRECAUTIONS, POTENTIAL ADVERSE REACTIONS:

Cardiovascular: myocardial infarction, heart failure
 Central nervous system: headache, fatigue
 Immunologic: hypersensitivity reactions, anaphylaxis
 Local: injection site reaction

ADDITIONAL NOTES AND NURSING CONSIDERATIONS:

- Prescriber must be available to attend the patient care area during administration.
- Dosage adjustment not required in renal dysfunction or hepatic dysfunction
- **RECOMMENDED MONITORING:**
 - Observe patient for hypersensitivity reactions for at least one hour after injection